Digital Therapeutics for Fibromyalgia Market Report 2026

The digital therapeutics for fibromyalgia market size has grown exponentially in recent years. It will grow from $1.19 billion in 2025 to $1.44 billion in 2026 at a compound annual growth rate (CAGR) of 21.1%. The growth in the historic period can be attributed to growing awareness of fibromyalgia management needs, rising acceptance of digital health solutions, increased smartphone penetration in healthcare, expansion of telehealth services, limitations of traditional pain management approaches.

The digital therapeutics for fibromyalgia market size is expected to see exponential growth in the next few years. It will grow to $3.07 billion in 2030 at a compound annual growth rate (CAGR) of 20.8%. The growth in the forecast period can be attributed to increasing demand for personalized chronic pain management, rising integration of ai-driven therapy optimization, expansion of remote care reimbursement models, growing focus on data-driven treatment personalization, increasing collaboration between clinicians and digital health providers. Major trends in the forecast period include increasing adoption of symptom-tracking mobile therapies, rising use of personalized digital care plans, growing integration of wearables with therapeutic platforms, expansion of remote patient monitoring programs, enhanced focus on patient engagement and adherence.

The increasing awareness of digital health solutions is expected to drive the growth of the digital therapeutics for fibromyalgia market in the coming years. Digital health solutions are software-based tools and services, including patient apps, patient portals, and virtual-care platforms, that provide information, monitoring, and therapy through digital channels. This growing awareness is driven by government-supported initiatives and the widespread adoption of official health apps, which make online access to care more common and accepted. Digital therapeutics for fibromyalgia capitalize on this familiarity by engaging patients through these channels, simplifying onboarding and adherence to app-based cognitive behavioral therapy, pacing, and sleep programs, while allowing clinician oversight. For example, in December 2023, the National Health Service, a UK government department, reported that digital health app users reached 33.6 million, up from 16.8 million in 2022, with monthly logins increasing 54% from 16.8 million to 25.8 million. Thus, the rising awareness of digital health solutions is fueling the digital therapeutics for fibromyalgia market.

Major companies operating in the digital therapeutics for fibromyalgia market are concentrating on technological innovations such as computerized behavioral therapy devices to provide evidence-based interventions that enhance pain management, alleviate fatigue, improve sleep quality, and support mental health, all through scalable, patient-focused digital platforms. A computerized behavioral therapy device is a software-based digital platform or application that delivers structured, evidence-based cognitive or behavioral therapy interventions to patients remotely, often using interactive modules, exercises, and real-time feedback to address symptoms of conditions such as fibromyalgia. For example, in May 2023, Swing Therapeutics, Inc., a US-based biopharmaceutical company, introduced Stanza following U.S. FDA De Novo marketing authorization (DEN220083). It provides a 12-week, self-guided acceptance and commitment therapy (ACT) program for fibromyalgia, with a randomized controlled trial published in The Lancet showing significant clinical improvements. This program is delivered via smartphone (iOS or Android), allowing patients to access therapy conveniently at home through the app.

In February 2025, XRHealth Inc., a US-based therapeutic extended reality (XR) and digital-therapeutics company, acquired RealizedCare for an undisclosed amount. Through this acquisition, XRHealth plans to incorporate RealizedCare’s immersive digital-therapeutics content and artificial intelligence triage tool into its platform to expand evidence-based care for chronic pain and behavioral health, including XRHealth’s existing fibromyalgia programs, while enhancing artificial intelligence-enabled, value-based delivery and improving clinician oversight and personalization. RealizedCare is a US-based immersive digital-therapeutics company specializing in chronic pain and behavioral health.

Major companies operating in the digital therapeutics for fibromyalgia market are Grünenthal GmbH, Hinge Health Inc., DarioHealth Corp., Kaia Health, CogniFit Inc., Big Health Ltd., Remedee Labs, HelloBetter GmbH, AppliedVR Inc., PainDrainer, Swing Therapeutics Inc., Fern Health Inc., JOGO Health Inc., LIN Health Inc., MoreGoodDays, Happify Health Inc., Click Therapeutics Inc., Wellthy Therapeutics Pvt. Ltd., FlexifyMe, SleepioRx.

North America was the largest region in the digital therapeutics for fibromyalgia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the digital therapeutics for fibromyalgia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the digital therapeutics for fibromyalgia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the digital therapeutics for fibromyalgia market by increasing costs associated with imported wearable devices, smart sensors, cloud infrastructure hardware, and specialized monitoring components used alongside software platforms. Healthcare providers and digital health companies in North America and Europe are most affected due to reliance on imported connected devices, while Asia-Pacific faces pricing pressure on device manufacturing and exports. These tariffs can raise solution costs and slow large-scale deployment across hospital and homecare settings. However, they are also encouraging domestic device manufacturing, regional sourcing of hardware components, and greater emphasis on software-centric therapeutic models that reduce long-term hardware dependence.

The digital therapeutics for fibromyalgia market research report is one of a series of new reports that provides digital therapeutics for fibromyalgia market statistics, including digital therapeutics for fibromyalgia industry global market size, regional shares, competitors with a digital therapeutics for fibromyalgia market share, detailed digital therapeutics for fibromyalgia market segments, market trends and opportunities, and any further data you may need to thrive in the digital therapeutics for fibromyalgia industry. This digital therapeutics for fibromyalgia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Digital therapeutics for fibromyalgia are mobile applications and web-based programs that provide structured therapy and monitor symptoms to aid daily self-management. Their aim is to reduce pain and fatigue, enhance sleep and functionality, and provide patients and healthcare providers with valuable data to tailor treatment.

The main product types of digital therapeutics for fibromyalgia include software applications, devices, and platforms. Software applications are clinically validated programs developed to deliver therapeutic interventions for managing fibromyalgia symptoms, such as pain and fatigue. These solutions are made available through both online and offline channels. Key applications include chronic pain management, sleep disorder management, fatigue management, and others, with primary end users comprising hospitals, clinics, homecare services, and others.

The digital therapeutics for fibromyalgia market consists of revenues earned by entities by providing services such as remote health coaching and therapist support, tele-physiotherapy consultations, adherence and engagement services, and outcomes analytics and reporting. The market value includes the value of related goods sold by the service provider or included within the service offering. The digital therapeutics for fibromyalgia market also includes sales of cognitive behavioral therapy (cbt) apps, pain neuroscience education modules, digital graded exercise and activity pacing programs, virtual reality-based pain distraction experiences, and sleep hygiene and relaxation programs, clinician dashboards and care coordination tools, patient. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.